%0 Journal Article
%A TAKAAKI MASUDA
%A MIWA NODA
%A AKIHIRO KITAGAWA
%A QINGJIANG HU
%A ATSUSHI FUJII
%A SHUHEI ITO
%A KEISUKE KOSAI
%A YUKI ANDO
%A YOSHIHIRO MATSUMOTO
%A HAJIME OHTSU
%A HIROKI UCHIDA
%A SHINJI OHNO
%A KOSHI MIMORI
%T The Expression Level of PD-L1 (CD274) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer
%D 2020
%R 10.21873/anticanres.14362
%J Anticancer Research
%P 3733-3742
%V 40
%N 7
%X Background/Aim: Programmed death-ligand 1 (PD-L1/CD274) elicits T-cell anergy, leading to immune suppression. We aimed to determine the prognostic relevance of PD-L1 expression in the blood of breast cancer (BC) patients. Materials and Methods: We measured PD-L1 mRNA expression in blood and tumor tissues of BC patients using RT-qPCR and a dataset from The Cancer Genome Atlas, and performed a survival analysis of PD-L1 expression in the blood of 330 BC patients. Flow cytometric analysis was performed using blood cells. Results: No statistical difference in PD-L1 expression was seen between normal controls and BC in blood or tissues. There was a significant positive correlation between the PD-L1 expression levels in blood and tissues. Decreased PD-L1 expression in blood or tissues was associated with poor recurrence-free survival. PD-L1 is mainly expressed in polymorphonuclear leukocytes. Conclusion: Low expression of PD-L1 in the blood could serve as a biomarker of poor prognosis in BC patients.
%U https://ar.iiarjournals.org/content/anticanres/40/7/3733.full.pdf